Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · Real-Time Price · USD

33.75

+0.21 (0.63%)

At close: Nov 17, 2025, 4:00 PM EST

34.20

+0.45 (1.33%)

After-hours: Nov 17, 2025, 7:40 PM EST

Cogent Biosciences Employees

Cogent Biosciences had 205 employees as of December 31, 2024. The number of employees increased by 41 or 25.00% compared to the previous year.

Employees

205

Change (1Y)

41

Growth (1Y)

25.00%

Revenue / Employee

n/a

Profits / Employee

-$1,435,961

Market Cap

5.13B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	205	41	25.00%
Dec 31, 2023	164	26	18.84%
Dec 31, 2022	138	61	79.22%
Dec 31, 2021	77	62	413.33%
Dec 31, 2020	15	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

COGT News

3 days ago - Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewsWire
6 days ago - Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 - GlobeNewsWire
6 days ago - Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside - Seeking Alpha
7 days ago - Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewsWire
7 days ago - Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy - Seeking Alpha
7 days ago - Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript - Seeking Alpha
7 days ago - Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial - Benzinga
7 days ago - Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire